Chemogenomics is the study of genomics genomic responses to chemical compound s. The goal is the rapid identification of novel drug s and drug target s, embracing multiple early phase drug development drug discovery technologies ranging from drug target identification target identification and drug target validation validation , through compound design and chemical synthesis , to biological testing and ADME profiling. See also Genomics Structural genomics Pharmacogenetics Pharmacogenomics Toxicogenomics Bioinformatics Cheminformatics Computational chemistry Molecular modelling QSAR Proteochemometrics References Chemogenomics in Drug Discovery A Medicinal Chemistry Perspective , H. Kubinyi Editor , G. M ller Editor , R. Mannhold Series Editor , G. Folkers Series Editor , Wiley VCH, 2004 .ISBN 3 527 30987 X External links http www.kubinyi.de dd 03.pdf Kubinyi s slides Medicinal chemistry genomics footer pharma stub Category Computational chemistry Category Genomics Category Omics Category Pharmacology Category Pharmaceutical industry Category Cheminformatics Ar de Chemische Genetik fr Chimiog nomique ko ... more details
A condition s gene signature is the group of gene s in a type of Cell biology cell whose combined Gene expression expression pattern ref Itadani H, Mizuarai S, Kotani H. Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics. 2008 Aug 9 5 349 60.PMID 19517027 ref is uniquely characteristic of that condition. ref Liu J, Campen A, Huang S, Peng SB, Ye X, Palakal M, Dunker AK, Xia Y, Li S. Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. BMC Med Genomics. 2008 Sep 11 1 39. PMID 18786252 ref Ideally, the gene signature can be used to select a group of patients ref Wouters BJ, L wenberg B, Erpelinck Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009 Mar 26 113 13 3088 91. Epub 2009 Jan 26.PMID 19171880 ref at a specific state of a disease with accuracy that facilitates selection of treatments. ref Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cell s using an in silico screen of public gene expression data. Blood. 2008 Jun 15 111 12 5654 62. Epub 2008 Feb 27.PMID 18305216 ref ref Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K. Identification of AML1 ETO modulators by Chemogenomics chemical genomics . Blood. 2009 Jun 11 113 24 6193 205. Epub 2009 Apr 17. PMID 19377049 ref See also Genomic signature References references DEFAULTSORT Gene Signature Category Genetics genetics stub ... more details
Leslie Johnston Browne pronounced Brown 3 February 1950, Glasgow , Scotland is a chemist and entrepreneur . Browne made important drug discoveries throughout the late 20th and early 21st century in the pharmaceutical industry . His most well known commercialized contributions include drugs for the treatment of various forms of cancer and cardiovascular disease. In addition to the discovery of http www.jco.org cgi content abstract 10 1 111 Fadrozole , the first marketed non steroidal aromatase inhibitor for the treatment of estrogen dependent breast cancer, he led the team that discovered http www.diovan.com Diovan , the second angiotensin II antagonist ever to be marketed. He has been a pharmaceutical industry leader and visionary for the last decade making public speaking appearances at both business and technical conferences across the globe. Browne is widely considered to be one of the drug discovery s most versatile leaders of the early 21st century combining world leading acumen in hands on drug discovery with some of the managerial acumen of a seasoned entrepreneur. He is also a prolific writer having authored numerous publications and patents covering a broad range of therapeutic areas including Central nervous system CNS , cardiovascular disease , inflammation and cancer . He currently has 17 patents to his name. Dr. Browne has over twenty years of experience in the pharmaceutical industry and has devoted the most distinguished years of his career to entrepreneurship in the pharmaceutical space. He was the President and CEO of http www.pharmacopeia.com wt page index Pharmacopeia Drug Discovery . Dr. Browne was the Chief Operating Officer at http www.iconixbiosciences.com Iconix Pharmaceuticals , a leading chemogenomics company, where he led the research, development and informatics operations and launched Iconix s first product, http www.iconixbiosciences.com products products drugmatrix.html DrugMatrix . Dr. Browne started his career working for the pharma ... more details
offered alternative terms such as chemogenomics to describe essentially the same area Fielden et al ... toxsci kfl103 ref See also Comparative Toxicogenomics Database Genomics Chemogenomics Structural ... more details
orphan date October 2011 wikify date October 2011 infobox biodatabase title TDR Targets logo File Database.png description Chemogenomics resource for neglected diseases scope Genomics, Medicinal Chemistry organism Various Neglected, Tropical Diseases center UNSAM , UPENN , University of Washington laboratory Laboratory of Genomics and Bioinformatics, UNSAM author Fern n Ag ero, Santiago Carmona, Mar a Paula Magari os, Dhanasekaran Shanmugam, Gregory Crowther, Stuart Ralph, David Roos, Wes Van Voorhis pmid Ag ero et al. 2008 ref name pmid18927591 released 2007 standard format url http tdrtargets.org download webservice sql sparql webapp Perl MVC Catalyst, DBIx Class, Template Toolkit standalone license versioning frequency 6 9 months curation yes bookmark version 5 The TDR Targets database is a bioinformatics project that seeks to exploit the availability of diverse genomic and chemical datasets to facilitate the identification and prioritization of drugs and drug targets in neglected disease pathogens ref Cite web url http tdrtargets.org title TDR Targets website http tdrtargets.org ref . TDR in the name of the database stands from the popular abbreviation for a special programme within the World Health Organization, whose focus is T ropical D isease R esearch. The project was jumpstarted by funds from this programme see User Rnanfe TDR Special Programme for Research and Training in Tropical Diseases , and the initial focus of the resource was on organisms diseases of high priority for this Programme. The database functions both as a website, where researchers can look for information on targets or compounds of interest, or as a tool for prioritization of targets in whole genomes ref name pmid18927591 cite journal author year 2007 month title Genomic scale prioritization of drug targets the TDR Targets database. journal Nature Reviews Drug Discovery volume 7 issue pages 900 907 id pmid 18927591 doi 10.1038 nrd2684 ref . When prioritizing genes, individual database q ... more details
Encyclopedia
top
